COMP <GO>
PRAX vs MRK // 10Y YIELD & FRED MACRO BETA
Praxis Precision Medicines Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: PRAX 2
— MRK 11
▲ 10Y YIELD & FRED MACRO BETA LEADER: MRK
LAST: $285.93 (-0.93%) • MKT CAP: $8.06B
macro-sensitivity
0.91
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
macro-sensitivity
0.92
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRAX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PRAX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 44.00% | 74.80% | -30.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.09% | 3.42% | -6.51 | MRK | /fcf-yield <GO> |
| Operating Margin | 16.50% | 34.30% | -17.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 28.10% | -15.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 8.80% | 1.30% | +7.50 | PRAX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.19 | +20.81 | PRAX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.60% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.0 | 56.9 | -1.84 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.91 | 0.92 | -0.01 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 18.4x | +14.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.06B | $361.02B | -$352.96B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PRAX REV | MRK REV | PRAX GROSS % | MRK GROSS % | PRAX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.01B | — | 74.8% | -$249.1M | $12.36B |
| FY 2024 | $8.6M | $64.17B | 44.0% | 76.3% | -$131.8M | $18.10B |
| FY 2023 | $2.4M | $60.12B | 44.0% | 44.0% | -$111.2M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRAX // BETA 0.91
MRK // BETA 0.92